BR112021006153A2 - anticorpo monoclonal beta amiloide anti-n-truncado humanizado - Google Patents
anticorpo monoclonal beta amiloide anti-n-truncado humanizado Download PDFInfo
- Publication number
- BR112021006153A2 BR112021006153A2 BR112021006153-3A BR112021006153A BR112021006153A2 BR 112021006153 A2 BR112021006153 A2 BR 112021006153A2 BR 112021006153 A BR112021006153 A BR 112021006153A BR 112021006153 A2 BR112021006153 A2 BR 112021006153A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- seq
- nt4x
- chain variable
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816210.7 | 2018-10-04 | ||
| GB201816210 | 2018-10-04 | ||
| PCT/EP2019/076772 WO2020070225A1 (en) | 2018-10-04 | 2019-10-02 | Humanised anti-n-truncated amyloid beta monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021006153A2 true BR112021006153A2 (pt) | 2021-06-29 |
Family
ID=68136417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021006153-3A BR112021006153A2 (pt) | 2018-10-04 | 2019-10-02 | anticorpo monoclonal beta amiloide anti-n-truncado humanizado |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12297261B2 (https=) |
| EP (1) | EP3861023A1 (https=) |
| JP (1) | JP7610515B2 (https=) |
| KR (1) | KR102862077B1 (https=) |
| CN (1) | CN113056480B (https=) |
| AU (1) | AU2019354714A1 (https=) |
| BR (1) | BR112021006153A2 (https=) |
| CA (1) | CA3114669A1 (https=) |
| EA (1) | EA202190954A1 (https=) |
| IL (1) | IL281979B2 (https=) |
| MX (1) | MX2021003867A (https=) |
| SG (1) | SG11202102765RA (https=) |
| WO (1) | WO2020070225A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4118111A1 (en) | 2020-03-10 | 2023-01-18 | LifeArc | Cyclic peptides |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| PE20252307A1 (es) | 2022-12-22 | 2025-09-22 | Bioarctic Ab | Anticuerpo que se une a abetape3 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US474900A (en) | 1892-05-17 | William byrnes | ||
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| WO2008081008A1 (en) * | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| MY155144A (en) | 2007-10-29 | 2015-09-15 | Inst Nat Sante Rech Med | NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
| WO2011151076A2 (en) * | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| EP2847217B1 (en) | 2012-05-10 | 2017-10-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta |
| WO2015173133A1 (en) | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| CA2992386A1 (en) * | 2015-07-16 | 2017-01-19 | Probiodrug Ag | Humanized antibodies |
| CN111518206B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| EP4118111A1 (en) * | 2020-03-10 | 2023-01-18 | LifeArc | Cyclic peptides |
-
2019
- 2019-10-02 BR BR112021006153-3A patent/BR112021006153A2/pt unknown
- 2019-10-02 CA CA3114669A patent/CA3114669A1/en active Pending
- 2019-10-02 KR KR1020217012796A patent/KR102862077B1/ko active Active
- 2019-10-02 IL IL281979A patent/IL281979B2/en unknown
- 2019-10-02 JP JP2021543565A patent/JP7610515B2/ja active Active
- 2019-10-02 SG SG11202102765RA patent/SG11202102765RA/en unknown
- 2019-10-02 EP EP19782593.8A patent/EP3861023A1/en active Pending
- 2019-10-02 AU AU2019354714A patent/AU2019354714A1/en active Pending
- 2019-10-02 US US17/282,592 patent/US12297261B2/en active Active
- 2019-10-02 CN CN201980065883.5A patent/CN113056480B/zh active Active
- 2019-10-02 WO PCT/EP2019/076772 patent/WO2020070225A1/en not_active Ceased
- 2019-10-02 EA EA202190954A patent/EA202190954A1/ru unknown
- 2019-10-02 MX MX2021003867A patent/MX2021003867A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3114669A1 (en) | 2020-04-09 |
| JP7610515B2 (ja) | 2025-01-08 |
| MX2021003867A (es) | 2021-09-08 |
| JP2022513331A (ja) | 2022-02-07 |
| EA202190954A1 (ru) | 2021-06-29 |
| US20210347867A1 (en) | 2021-11-11 |
| EP3861023A1 (en) | 2021-08-11 |
| CN113056480A (zh) | 2021-06-29 |
| AU2019354714A1 (en) | 2021-04-29 |
| SG11202102765RA (en) | 2021-04-29 |
| KR102862077B1 (ko) | 2025-09-18 |
| IL281979B2 (en) | 2025-09-01 |
| KR20210080400A (ko) | 2021-06-30 |
| US12297261B2 (en) | 2025-05-13 |
| IL281979B1 (en) | 2025-05-01 |
| IL281979A (en) | 2021-05-31 |
| CN113056480B (zh) | 2025-06-13 |
| US20230203140A9 (en) | 2023-06-29 |
| WO2020070225A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1426423B (zh) | 螯合淀粉样蛋白β肽的人源化抗体 | |
| BR112021006153A2 (pt) | anticorpo monoclonal beta amiloide anti-n-truncado humanizado | |
| ES2529174T3 (es) | Anticuerpos humanizados para amiloide beta | |
| EP2205631B1 (en) | Methods and compositions for diagnosis and treatment of amyloidosis | |
| JP7045724B2 (ja) | 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途 | |
| RU2771384C2 (ru) | Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение | |
| KR20190082815A (ko) | 중화 항-tl1a 단일 클론 항체 | |
| US20250353915A1 (en) | Antibodies to galectin-3 and methods of use thereof | |
| BR112020006434A2 (pt) | anticorpos anti-transtirretina | |
| TW201620933A (zh) | 抗體－飛諾莫接合物 | |
| AU2007275467A1 (en) | Humanized antibody against amyloid beta | |
| BRPI0719763A2 (pt) | Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero. | |
| BR112019025048A2 (pt) | anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos | |
| CN107074937A (zh) | 人源抗亨廷顿蛋白（htt）抗体及其用途 | |
| WO2022125482A1 (en) | Antibodies to galectin-3 and methods of use thereof | |
| BR112012002819B1 (pt) | Anticorpo humanizado antioligômero de amiloide-b, seus usos, e formulação farmacêutica | |
| JP2025041747A (ja) | ヒト化抗ｉｌ１７ｂｒ抗体 | |
| WO2023025249A1 (zh) | 一种含融合蛋白的药物组合物 | |
| AU2013202799A1 (en) | Humanized antibody against amyloid beta | |
| HK1140499B (en) | Methods and compositions for diagnosis and treatment of amyloidosis | |
| HK1140499A (en) | Methods and compositions for diagnosis and treatment of amyloidosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |